![]() |
Name |
(E)-7-(3-methyl-4-oxo-6,7,8,8a-tetrahydro-4H-pyrrolo[2,1-b][1,3]oxazin-2-yl)hept-2-enoic acid
|
Molecular Formula | C15H21NO4 | |
IUPAC Name* |
(E)-7-(3-methyl-4-oxo-6,7,8,8a-tetrahydropyrrolo[2,1-b][1,3]oxazin-2-yl)hept-2-enoic acid
|
|
SMILES |
CC1=C(OC2CCCN2C1=O)CCCC/C=C/C(=O)O
|
|
InChI |
InChI=1S/C15H21NO4/c1-11-12(7-4-2-3-5-9-14(17)18)20-13-8-6-10-16(13)15(11)19/h5,9,13H,2-4,6-8,10H2,1H3,(H,17,18)/b9-5+
|
|
InChIKey |
VAXDOPFIFJJTAB-WEVVVXLNSA-N
|
|
Synonyms |
(E)-7-(3-methyl-4-oxo-6,7,8,8a-tetrahydro-4H-pyrrolo[2,1-b][1,3]oxazin-2-yl)hept-2-enoic acid
|
|
CAS | NA | |
PubChem CID | 139585767 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 279.33 | ALogp: | 2.2 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 20 | QED Weighted: | 0.599 |
Caco-2 Permeability: | -5.141 | MDCK Permeability: | 0.00007990 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.007 |
Human Intestinal Absorption (HIA): | 0.013 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.007 |
Blood-Brain-Barrier Penetration (BBB): | 0.51 | Plasma Protein Binding (PPB): | 77.23% |
Volume Distribution (VD): | 0.308 | Fu: | 18.90% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.094 |
CYP2C19-inhibitor: | 0.03 | CYP2C19-substrate: | 0.108 |
CYP2C9-inhibitor: | 0.006 | CYP2C9-substrate: | 0.946 |
CYP2D6-inhibitor: | 0.031 | CYP2D6-substrate: | 0.165 |
CYP3A4-inhibitor: | 0.038 | CYP3A4-substrate: | 0.049 |
Clearance (CL): | 5.898 | Half-life (T1/2): | 0.787 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.398 |
Drug-inuced Liver Injury (DILI): | 0.053 | AMES Toxicity: | 0.012 |
Rat Oral Acute Toxicity: | 0.002 | Maximum Recommended Daily Dose: | 0.581 |
Skin Sensitization: | 0.604 | Carcinogencity: | 0.427 |
Eye Corrosion: | 0.126 | Eye Irritation: | 0.109 |
Respiratory Toxicity: | 0.036 |